MRTX News and Press, Mirati Therapeutics Inc. From 02/25/21

Mirati Therapeutics (MRTX): Q4 GAAP EPS of -$2.08 beats by $0.17.Revenue of $1.71M (+222.6% Y/Y) beats by $1.41M.Cash, cash equivalents, and short-term investments of $1.4B.Press Release For further details see: Mirati Therapeutics EPS beats by $0.17, beats on revenue

Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates PR Newswire SAN DIEGO , Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today repo...

MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors PR Newswire HOUSTON and SAN DIEGO , Feb. 10, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Mirati The...

Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days PR Newswire SAN DIEGO , Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a ...

Our Roundtable series continues with a focus on biotech and healthcare investing. Apart from COVID-19 and vaccines, opportunities abound. The series will end this week with growth/tech investing and macro and technical analysis. For further details see: 2021 Roundtable: ...

Resolution Bioscience and Mirati Therapeutics (MRTX) enter companion diagnostic tie-up where Resolution’s ctDx liquid biopsy technology will be used to help identify non-small cell lung cancer ((NSCLC)) patients who may benefit from Mirati’s investigational K...

Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P...

Mirati shares have been on a tear throughout most of 2020 but a recent dip to $219.5 at the time of writing makes for an attractive investment opportunity. The company is pioneering a new type of KRAS G12C mutation targeting small molecule which, alongside Amgen's Sotorasib, is a long...

Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications. I recommend Mirati a buy and I raised the rating from four to five out of five stars. Fo...

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...